On the stock market since 2012, it operates in the world of health and science. It has 497 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 65% a year on average.
Sales run at $490.7M a year. A small number, but proof the product has real buyers.
A loss of $25.5M against $490.7M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 9/100.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, TVTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TVTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.